Aim To investigate the association between type 2 diabetes mellitus (T2DM) and pulmonary embolism, as well as to determine the prognostic value of troponin, D-dimer, prothrombotic, and proinflammatory markers in patients with T2DM. Methods The retrospective cohort study included 305 patients with pulmonary embolism, divided into two groups: the first group with type 2 diabetes mellitus (n=165) and the control group without type 2 diabetes mellitus (n=140). Data were collected from May 2018 to May 2023. In all patients the following parameters were analysed: anthropometric parameters, laboratory parameters (troponin, D-dimer, CRP, fibrinogen, uric acid, glucose, total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides), arterial blood pressure, antiphospholipid antibodies, HOMA-IR index, CT angiography of the pulmonary artery, rate of adverse clinical events in pulmonary embolism (need for inotropic catecholamine support, fibrinolysis, cardiopulmonary resuscitation) and the rate of intrahospital mortality from pulmonary embolism. Results Patients with T2DM had elevated troponin, D-dimer, CRP, uric acid, fibrinogen, HOMA-IR and more severe clinical complications with higher mortality rates within 10 days of hospital admission. Significant predictors of PE in T2DM patients were found. Patients with pulmonary embolism in T2DM had a 4.38 times higher chance of death compared to patients with pulmonary embolism without T2DM. Conclusions Troponin, D-dimer, prothrombotic, and proinflammatory markers have good prognostic value for short-term outcomes in PE among patients with T2DM
Stewart LK, Kline JA. Metabolic syndrome increases risk of venous thromboembolism recurrence after acute pulmonary embolism. Ann Am Thorac Soc. 2020;17:821–8.
2.
O’Hara A, Pozin J, Darki A, Siddiqui F, Hoppensteadt D, Walenga J, et al. Glycemic control and plasma levels of pro-inflammatory and pro-thrombotic biomarkers in diabetic patients presenting with acute pulmonary embolism. Clin Appl Thromb Hemost. 2023;29(10760296231165058).
3.
Goldhaber SZ. Venous thromboembolism: epidemiology and magnitude of the problem. Best Pract Res Clin Haematol. 2012;25:235–42.
4.
L.M. K, E.R H. Screening and diagnosis of VTE: the more you look, the more you find? Curr Trauma Rep. 2016;29–34.
5.
Ageno W, Prandoni P, Romualdi E, Ghirarduzzi A, Dentali F, Pesavento R. The metabolic syndrome and the risk of venous thrombosis: a case-control study. J Thromb Haemost. 2006;4:1914–8.
6.
Jang MJ, Choi WI, Bang SM, Lee T, Kim YK, Ageno W, et al. Metabolic syndrome is associated with venous thromboembolism in the Korean population. Arterioscler Thromb Vasc Biol. 2009;29:311–5.
7.
Vayá A, Martínez-Triguero ML, España F, Todolí JA, Bonet E, Corella D. The metabolic syndrome and its individual components: its association with venous thromboembolism in a Mediterranean population. Metab Syndr Relat Disord. 2011;9:197–201.
8.
Borch KH, Braekkan SK, Mathiesen EB, Njølstad I, Wilsgaard T, Størmer J, et al. Abdominal obesity is essential for the risk of venous thromboembolism in the metabolic syndrome: the Tromsø study. J Thromb Haemost. 2009;7:739–45.
9.
Molica F, Morel S, Kwak BR, Rohner-Jeanrenaud F, Steffens S. Adipokines at the crossroad between obesity and cardiovascular disease. Thromb Haemost. 2015;113:553–66.
10.
Summer R, Walsh K, Medoff BD. Obesity and pulmonary arterial hypertension: Is adiponectin the molecular link between these conditions? Pulm Circ. 2011;1:440–7.
11.
MW EH, M M, S S, A IA, MM Z, OM A, et al. Adipokines: Potential therapeutic targets for vascular dysfunction in type II diabetes mellitus and obesity. J Diabetes Res. 2017;2:8095–926.
12.
Li X, Weber NC, Cohn DM, Hollmann MW, DeVries JH, Hermanides J, et al. Effects of Hyperglycemia and Diabetes Mellitus on Coagulation and Hemostasis. J Clin Med. 2021;10(2419).
13.
Cho NH, Shaw JE, Karuranga S, Huang Y, Rocha Fernandes JD, Ohlrogge AW, et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271–81.
14.
Leidi A, Bex S, Righini M, Berner A, Grosgurin O, Marti C. Risk stratification in patients with acute pulmonary embolism: current evidence and perspectives. J Clin Med. 2022;30:11–2533.
15.
Dhananjayan R, Koundinya KS, Malati T, Kutala VK. Endothelial dysfunction in type 2 diabetes mellitus. Indian J Clin Biochem. 2016;31:372–9.
16.
E DC, A C, L R, M F, TB H, O S, et al. Diabetes as a cardiovascular risk factor: an overview of global trends of macro and micro vascular complications. Eur J Prev Cardiol. 2019;26:25–32.
17.
Sudi KM, Gallistl S, Tröbinger M, Payerl D, Weinhandl G, Muntean W, et al. The influence of weight loss on fibrinolytic and metabolic parameters in obese children and adolescents. J Pediatr Endocrinol Metab. 2001;14:85–94.
18.
Fujii S, Goto D, Zaman T, Ishimori N, Watano K, Kaneko T, et al. Diminished fibrinolysis and thrombosis: clinical implications for accelerated atherosclerosis. Journal of Atherosclerosis and Thrombosis. 1998;5:76–81.
19.
Fendri S, Roussel B, Lormeau B, Tribout B, Lalau JD. Insulin sensitivity, insulin action, and fibrinolysis activity in nondiabetic and diabetic obese subjects. Metabolism. 1998;47:1372–5.
20.
Janisset L, Castan M, Poenou G, Lachand R, Mismetti P, Viallon A, et al. Cardiac Biomarkers in patients with acute pulmonary embolism. Medicina (Kaunas. 2022;58(541).
21.
Becattini C, Agnelli G, Vedovati MC, Pruszczyk P, Casazza F, Grifoni S, et al. Multidetector computed tomography for acute pulmonary embolism: diagnosis and risk stratification in a single test. Eur Heart J. 2011;32:1657–63.
22.
Kahn de WKPENEJM. Vol. 387. 2022. p. 45–57.
23.
Monteleone PP, Rosenfield K, Rosovsky RP. Multidisciplinary pulmonary embolism response teams and systems. Cardiovasc Diagn Ther. 2016;6:662–7.
24.
Yang G, Staercke C, W.C H. The effects of obesity on venous thromboembolism: a review. Open J Prev Med. 2012;2:499–509.
25.
Association AD. Classification and diagnosis of diabetes: medical care in diabetes. Diabetes Care. 2021;44:15–33.
26.
Gender-specific alterations in fibrin structure function in type 2 diabetes: associations with cardiometabolic and vascular markers. J Clin Endocrinol Metab. 2012;97:2282–7.
27.
Martín-Timón I, Sevillano-Collantes C, Segura-Galindo A, Del Cañizo-Gómez FJ. Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength? World J Diabetes. 2014;15:444–70.
28.
Schmitt VH, Hobohm L, Sivanathan V, Brochhausen C, Gori T, Münzel T, et al. Diabetes mellitus and its impact on mortality rate and outcome in pulmonary embolism. J Diabetes Investig. 2022;13:725–37.
29.
Ray JG, Lonn E, Yi Q, Rathe A, Sheridan P, Kearon C, et al. Venous thromboembolism in association with features of the metabolic syndrome. QJM. 2007;100:679–84.
30.
Metabolic syndrome and risk of venous thromboembolism: longitudinal investigation of thromboembolism etiology. J Thromb Haemost. 2009;7:746–51.
31.
Wang Y, Wang P, Li H. Correlation study of pulmonary embolism and high-density lipoprotein cholesterol. Clin Cardiol. 2010;33:72–6.
32.
Shifa K, J T, K WP, Liji K. A Comparative study on plasma fibrinogen and hs-crp in metabolic syndrome. Int J Clin Biochem Res. 2015;2:162–5.
33.
Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation. 2003;107:391–7.
34.
Ozsu S, Çoşar AM, Aksoy HB, Bülbül Y, Oztuna F, Karahan SC, et al. Prognostic value of uric acid for pulmonary thromboembolism. Respir Care. 2017;62:1091–6.
35.
Demir OM, Ryan M, Cirillo C, Desai N, Pericao A, Sinclair H, et al. Impact and determinants of high-sensitivity cardiac troponin-T concentration in patients with COVID-19 admitted to critical care. Am J Cardiol. 2021;147:129–36.
36.
Kline JA, Hernandez-Nino J, Rose GA, Norton HJ, CA C. Surrogate markers for adverse outcomes in normotensive patients with pulmonary embolism. Crit Care Med. 2006;34:2773–80.
37.
Bulj N, Potočnjak I, Sharma M, Pintaric H, Degoricija V. Timing of troponin T measurements in triage of pulmonary embolism patients. Croat Med J. 2013;54:561–8.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
